| CAS: | 298197-04-3 | ||||
| 分子式: | C18H18N2S·HBr | ||||
| 分子量: | 375.33 | ||||
| 中文名称: |
| ||||
| 英文名称: |
| ||||
| 用途: | Fatostatin是固醇调节元件结合蛋白(SREBP)的抑制剂。它损害SREBP-1和SREBP-2的激活。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||||||||||||||
| F798371 | MACKLIN | Fatostatin HBr | 10mM in DMSO | 608元/1ml; | 展开 | ||||||||||||||||||||||||||||||||
储存：-20°C | |||||||||||||||||||||||||||||||||||||
| F872602 | MACKLIN | Fatostatin HBr | 98% | 245元/5mg; 818元/25mg; | 展开 | ||||||||||||||||||||||||||||||||
储存：-20℃ 状态：粉末 | |||||||||||||||||||||||||||||||||||||
| F8932 | Sigma-Aldrich | Fatostatin hydrobromide | ≥98% (HPLC), powder | 1181.99元/5 MG; 6488.23元/25 MG; | 展开 | ||||||||||||||||||||||||||||||||
产品说明 一般描述 Fatostatin是一种非固醇二芳基噻唑衍生物。它可防止胰岛素诱导的脂肪生成，并降低脂肪酸、甘油三酯和低密度脂蛋白的含量。Fatostatin具有抗肿瘤和抗有丝分裂特性。 应用 Fatostatin氢溴酸已被用于：
包装 5, 25 mg in glass bottle 生化/生理作用 Fatostatin氢溴酸是一种SREBP抑制剂。Fatostatin氢溴酸可通过抑制SREBP(固醇调节元素结合蛋白)来抑制小鼠脂肪的产生并降低葡萄糖水平。 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||
| 341329 | Sigma-Aldrich | Fatostatin-CAS 298197-04-3-Calbiochem | A cell-permeable diarylthiazole compound that prevents the cellular activation of the SREBP-1/2 precursors to the active nuclear forms by blocking SREBPs-SCAP ER to Golgi translocation. | 2566.78元/25 MG; | 展开 | ||||||||||||||||||||||||||||||||
产品说明 一般描述 A cell-permeable diarylthiazole compound that prevents the cellular activation of the SREBP-1/2 (Sterol Regulatory Element Binding Proteins 1/2) precursors to the active nuclear forms (>95% inhibition at 20 µM in CHO-K1 cells) by blocking SREBPs-SCAP (SREBP Cleavage-Activating Protein) ER to Golgi translocation with little effect against the transcription activity of the mature SREBPs. Binding studies employing recombinant SCAP truncation constructs reveal that Fatostatin targets SCAP between aa 448 to 767 in a reversible manner and is of no effect against SREBP-SCAP interaction. Fatostatin effectively suppresses SREBPs-dependent cellular functions in vitro, such as insulin-induced 3T3-L1 adipogenesis (complete inhibition at ≤20 µg/ml) and IGF1-dependent DU-145 proliferation (IC50 = 100 nM), and exhibits in vivo efficacy in lowering blood glucose level (by 70%) and body weight (by 12%) of ob/ob mice over a 28-day treatment period (30 mg/kg daily i.p.) without affecting animal food intake or apparent adverse effects. 包装 Packaged under inert gas 警告 Toxicity: Standard Handling (A) 重悬 Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C. 其他说明 Kamisuki, S., et al. 2009. Chem. Biol.16, 882. 法律信息 CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||
m.cnreagent.com